As Array Biopharma (ARRY) Valuation Rose, First Light Asset Management Has Raised Position by $1.17 Million; Mraz Amerine & Associates Maintains Stake in Consolidated Tomoka Ld Co (CTO)

April 16, 2018 - By Nellie Frank

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Mraz Amerine & Associates Inc increased its stake in Consolidated Tomoka Ld Co (CTO) by 25.58% based on its latest 2017Q4 regulatory filing with the SEC. Mraz Amerine & Associates Inc bought 8,845 shares as the company’s stock declined 1.54% with the market. The institutional investor held 43,420 shares of the real estate company at the end of 2017Q4, valued at $2.25 million, up from 34,575 at the end of the previous reported quarter. Mraz Amerine & Associates Inc who had been investing in Consolidated Tomoka Ld Co for a number of months, seems to be bullish on the $331.79M market cap company. The stock decreased 0.60% or $0.36 during the last trading session, reaching $59.3. About 12,900 shares traded. Consolidated-Tomoka Land Co. (NYSEMKT:CTO) has risen 20.23% since April 16, 2017 and is uptrending. It has outperformed by 8.68% the S&P500.

First Light Asset Management Llc increased its stake in Array Biopharma Inc (ARRY) by 6.62% based on its latest 2017Q4 regulatory filing with the SEC. First Light Asset Management Llc bought 97,343 shares as the company’s stock rose 29.01% while stock markets declined. The institutional investor held 1.57M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $20.06 million, up from 1.47M at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Array Biopharma Inc for a number of months, seems to be bullish on the $3.15B market cap company. It closed at $15.16 lastly. It is down 68.58% since April 16, 2017 and is uptrending. It has outperformed by 57.03% the S&P500.

Mraz Amerine & Associates Inc, which manages about $353.64M and $326.23 million US Long portfolio, decreased its stake in Markel Corp (NYSE:MKL) by 342 shares to 16,482 shares, valued at $18.78 million in 2017Q4, according to the filing.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma had 37 analyst reports since June 3, 2016 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Thursday, August 24. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Wednesday, August 9 by Stifel Nicolaus. As per Sunday, September 10, the company rating was maintained by Cowen & Co. On Tuesday, October 31 the stock rating was maintained by SunTrust with “Buy”. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Sunday, January 21 by Cowen & Co. Cantor Fitzgerald maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Tuesday, May 30. Cantor Fitzgerald has “Buy” rating and $1300 target. The firm has “Buy” rating by Stifel Nicolaus given on Friday, August 5. The firm earned “Buy” rating on Monday, August 29 by Jefferies. Piper Jaffray maintained Array BioPharma Inc. (NASDAQ:ARRY) on Wednesday, September 20 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Sunday, January 21 report.

Since December 16, 2017, it had 0 insider purchases, and 8 sales for $15.94 million activity. On Sunday, April 1 Sandor Victor sold $133,376 worth of Array BioPharma Inc. (NASDAQ:ARRY) or 8,689 shares. Shares for $278,210 were sold by VAN LUNSEN GIL J. $3.03 million worth of stock was sold by Robbins Andrew R on Saturday, December 16. 7,500 shares valued at $102,975 were sold by Haddock Jason on Tuesday, January 16.

Consolidated-Tomoka Land Co. (NYSEAMERICAN:CTO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>